Gregory Kaufman, MD
Hematology · Houston, TXNPI 1417211368
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (55.5%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Janssen Research & Development, LLC accounts for 73.4% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $1,946 and has fallen 89.9% since, to $198 in 2024.
Across 27 payments — averaging $97.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$2K
- Akcea Therapeutics, Inc.$150
- Janssen Scientific Affairs, LLC$150
- Sobi, Inc$150
- Legend Biotech USA Inc.$125
- Stemline Therapeutics Inc.$48
- plus $78 from 3 others
Across 61 payments — averaging $14,179 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$385K
- Bristol Myers Squibb$243K
- AstraZeneca$236K
What the payments were for
- Consulting fees$30011%
- Speaking & faculty fees$1506%
- Travel & lodging$1,46356%
- Food & beverage$72227%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 18 | $1,934 |
| Akcea Therapeutics, Inc. | 1 | $150 |
| Janssen Scientific Affairs, LLC | 1 | $150 |
| Sobi, Inc | 1 | $150 |
| Legend Biotech USA Inc. | 1 | $125 |
| Stemline Therapeutics Inc. | 1 | $48 |
| Mentor Worldwide LLC | 2 | $39 |
| GSK | 1 | $28 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,635 in reported general payments places this provider in the 55th percentile of 97 hematology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 95 | $1,466,441 |
| RevlimidLenalidomide | 79 | $1,278,094 |
| PomalystPomalidomide | 29 | $638,459 |
| XpovioSelinexor | 11 | $339,079 |
| ValacyclovirValacyclovir Hcl | 60 | $1,898 |
| Pantoprazole Sodium | 15 | $124 |
| Ondansetron Hcl | 11 | $66 |
Paid to pharmacies, not to this prescriber.
Other hematology in Houston
- Miguel EscobarHouston$767K
- Kelty BakerHouston$229K
- Siddhartha GangulyHouston$119K
- Lawrence RiceHouston$103K
- Modupe IdowuHouston$102K
- Swaminathan IyerHouston$50K
- Jing YeHouston$34K
- Senthil SukumarHouston$31K
- Sa WangHouston$27K
- Uday PopatHouston$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.